Dr. Gottlieb has been conducting NIH-funded cardiovascular research for the past 20 years. She has prior experience with The Scripps Research Institute (TSRI); SDSU where she became the first Director of the Donald P. Shiley BioScience Center, and currently as the Director of Molecular Cardiobiology at Cedars-Sinai Heart Institute.The work in her lab has led to the discovery of the cardioprotective agents and the elucidation of their novel mechanism of action. Her expertise in cardioprotection and autophagy is recognized on a national and international level. Dr. Gottlieb is also an entrepreneur, having started a biotechnology company called Radical Therapeutix, to develop drugs to mitigate the damage to the heart during myocardial infarction. Dr. Gottlieb received her B.S. and M.D. degrees from Johns Hopkins University.Dr. Mehta, MD, FACC is Director of the Non-invasive Vascular Function Research Laboratory in the Barbra Streisand Women's Heart Center at the Cedars-Sinai's Heart Institute. She is also Co-Director of the Cardio-Oncology Program, a clinic dedicated to the heart health of women after cancer treatment. Dr. Mehta is board certified in internal medicine and cardiovascular diseases and board-eligible in echocardiography and nuclear cardiology. She is a member of the American Heart Association, the American Society for Preventive Cardiology and the American College of Cardiology, where she is also a fellow. In addition to academic success, she has received numerous awards including the prestigious New Jersey Foundation Humanism in Medicine Award. She has published her research in peer-reviewed journals and presented at national cardiology meetings. Dr. Mehta's research is National Institutes of Health (NIH) funded and includes the role of mental stress in heart disease, exploring the brain-heart connection and new approaches to treating chest pain in women.Dr. Mehta's Scival Overall Research Performance 2009-2013: 30 Publications, 245 Citations, 1.64 Field-Weighted Citation Impact, 8.2 Citations per PublicationThe editors state that "We will probably enlist 2-3 more editors in order to balance the perspective, probably Melissa Hudson (oncologist) and Javid Mohslehi and "a hypertension expert (possibly Ron Victor) as a result of the reviewer feedback.